| Ytd | -12.77% | |
| 1y | 35.91% |
| Open | 2.49 | Prev Close | 2.43 | Low | 2.44 | High | 2.58 | Mkt Cap | 154.89M |
| Vol | 0.00 | Avg Vol | 429.49K | EPS | -0.61 | P/E | -4.03 | Forward P/E | -5.04 |
| Beta | -0.31 | Short Ratio | 1.93 | Inst. Own | 44.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-19 | 50-d Avg | 2.22 | 200-d Avg | 2.44 | 1yr Est | 7.00 |
CNTB News
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned
CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to rep
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart p
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Conne
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned ba
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phas
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or CO
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Upda
Funding from new and existing investors extends anticipated cash runway into the second half of 2027
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, w
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pu
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have ear
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Co
Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthc
BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Con
On Friday, 1043 companies hit new 52-week lows.
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after
During Thursday, 849 stocks hit new 52-week lows.